Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Gallbladder01:17

Gallbladder

2.8K
The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins...
2.8K
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

3.2K
Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
3.2K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

16.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.7K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.6K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

3.8K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
3.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective epidemiological study in an Aotearoa New Zealand cohort.

The New Zealand medical journal·2026
Same author

A Return to Normality: A Descriptive Qualitative Interview Study Exploring the Patient Experience of Gout Flare Resolution.

Arthritis care & research·2026
Same author

Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system.

Annals of the rheumatic diseases·2026
Same author

Mitonuclear Discordance and Gout, Type 2 Diabetes and Chronic Kidney Disease in Aotearoa New Zealand Indigenous Māori and Pacific People.

Annals of human genetics·2026
Same author

Revisiting the Ethics of Urate-Lowering Therapy Clinical Trials for Gout Management.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Misclassified latent autoimmune diabetes in adults within Māori and Pacific adults with type 2 diabetes in Aotearoa New Zealand.

The New Zealand medical journal·2025
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Mar 22, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K

La gota

Nicola Dalbeth1, Tony R Merriman2, Lisa K Stamp3

  • 1Department of Medicine, University of Auckland, Auckland, New Zealand.

Lancet (London, England)
|April 27, 2016
PubMed
Resumen
Este resumen es generado por máquina.

El tratamiento eficaz de la gota requiere reducir los niveles de urato sérico a menos de 360 μmol/L. A pesar de los tratamientos disponibles como el alopurinol, las bajas tasas de inicio y continuación de la terapia para reducir los uratos dificultan la supresión de los brotes.

Más Videos Relacionados

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.6K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Videos de Experimentos Relacionados

Last Updated: Mar 22, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
10:02

Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril

Published on: October 3, 2020

4.6K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Área de la Ciencia:

  • Reumatología
  • Artritis inducida por los cristales
  • Inmunología

Sus antecedentes:

  • La gota es una enfermedad crónica causada por la deposición de cristales de urato monosódico debido a un nivel elevado de urato sérico.
  • Los factores genéticos y ambientales influyen en la hiperuricemia, siendo la excreción renal y intestinal de los uratos los principales mecanismos reguladores.
  • La activación del inflamatorio NLRP3 y la liberación de la interleucina-1β son cruciales para iniciar los brotes agudos de gota.

Objetivo del estudio:

  • Hacer hincapié en la importancia de una estrategia de "tratamiento del urato sérico objetivo" para un tratamiento eficaz de la gota.
  • Resaltar el objetivo de la reducción del urato sérico a largo plazo a < 360 μmol/L para la disolución de los cristales y la supresión de la inflamación.
  • Identificar la necesidad de estrategias mejoradas en la calidad de la atención de la gota.

Principales métodos:

  • Revisión de la comprensión actual de la fisiopatología de la gota, incluida la formación de cristales y las vías inflamatorias.
  • Discusión de enfoques terapéuticos, incluida la escalada de la dosis de alopurinol y los fármacos más nuevos que reducen el urato.
  • Análisis de las tendencias mundiales en las tasas de inicio y continuación de la terapia de reducción de uratos.

Principales resultados:

  • El logro de los objetivos de urato sérico (<360 μmol/L) es esencial para el tratamiento de la gota, lo que lleva a la disolución de los cristales y la supresión de la inflamación.
  • La escalada de la dosis de alopurinol a menudo es efectiva, y están disponibles nuevos medicamentos para reducir el urato.
  • En todo el mundo, el inicio y la adherencia a la terapia para disminuir el nivel de uratos son subóptimos, lo que resulta en un logro poco frecuente de los objetivos del tratamiento.

Conclusiones:

  • Un enfoque de "tratamiento al urato sérico objetivo" es fundamental para el manejo eficaz de la gota.
  • Las bajas tasas actuales de utilización de la terapia de reducción de uratos impiden un tratamiento exitoso de la gota a nivel mundial.
  • Existe una necesidad crítica de estrategias mejoradas para mejorar la calidad de la atención de la gota y la adherencia del paciente al tratamiento.